EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Optimizing the approach to monitoring allograft inflammation using serial urinary CXCL10/creatinine testing in pediatric kidney transplant recipients

Ella Barrett-Chan iD, Li Wang iD, Jeffrey Bone iD, Amy Thachil, Kevin Vytlingam iD, Tom Blydt-Hansen iD

Pediatric Transplantation · 2024-05 · 28 (3)

DOI: 10.1111/petr.14718 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, online erschienen am 29.03.2024. Verfasst von Ella Barrett-Chan und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Kidney Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BC Children's Hospital Foundation, BC Children’s Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urinary CXCL10/creatinine (uCXCL10/Cr) is proposed as an effective biomarker of subclinical rejection in pediatric kidney transplant recipients. This study objective was to model implementation in the clinical setting.

Methods

Banked urine samples at a single center were tested for uCXCL10/Cr to validate published thresholds for rejection diagnosis (>80% specificity). The positive predictive value (PPV) for rejection diagnosis for uCXCL10/Cr‐indicated biopsy was modeled with first‐positive versus two‐test‐positive approaches, with accounting for changes associated with urinary tract infection (UTI), BK and CMV viremia, and subsequent recovery.

Results

Seventy patients aged 10.5 ± 5.6 years at transplant (60% male) had n = 726 urine samples with n = 236 associated biopsies (no rejection = 167, borderline = 51, and Banff 1A = 18). A threshold of 12 ng/mmol was validated for Banff 1A versus no‐rejection diagnosis (AUC = 0.74, 95% CI = 0.57–0.92). The first‐positive test approach ( n = 69) did not resolve a clinical diagnosis in 38 cases (55%), whereas the two‐test approach resolved a clinical diagnosis in the majority as BK ( n = 17/60, 28%), CMV ( n = 4/60, 7%), UTI ( n = 8/60, 13%), clinical rejection ( n = 5/60, 8%), and transient elevation ( n = 18, 30%). In those without a resolved clinical diagnosis, PPV from biopsy for subclinical rejection is 24% and 71% ( p = .017), for first‐test versus two‐test models, respectively. After rejection treatment, uCXCL10/Cr level changes were all concordant with change in it‐score. Sustained uCXCL10/Cr after CMV and BK viremia resolution was associated with later acute rejection.

Conclusions

Urinary CXCL10/Cr reliably identifies kidney allograft inflammation. These data support a two‐test approach to reliably exclude other clinically identifiable sources of inflammation, for kidney biopsy indication to rule out subclinical rejection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsKidney TransplantationChildFemaleHumansMaleAllograftsBiomarkersChemokine CXCL10CreatinineGraft RejectionInflammationKidneyTransplant RecipientsViremiaChild, PreschoolAdolescent

Stichwörter der Autor:innen

CXCL10biomarkersgraft rejectionkidneykidney transplantpediatric kidney transplantsubclinical rejection

Substanzen

BiomarkersChemokine CXCL10CreatinineCXCL10 protein, human

Autor:innen und Institutionen

  • University of British Columbia, Vancouver, British Columbia, Canada.
  • BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.

ORCID-Profile: Ella Barrett-Chan, Li Wang, Jeffrey Bone, Kevin Vytlingam, Tom Blydt-Hansen

Förderung

  • BC Children's Hospital Foundation
  • BC Children’s Hospital Foundation

Zitieren

APA

Barrett-Chan, E., Wang, L., Bone, J., Thachil, A., Vytlingam, K., & Blydt-Hansen, T. (2024). Optimizing the approach to monitoring allograft inflammation using serial urinary CXCL10/creatinine testing in pediatric kidney transplant recipients. Pediatric Transplantation, 28(3). https://doi.org/10.1111/petr.14718

Vancouver

Barrett-Chan E, Wang L, Bone J, Thachil A, Vytlingam K, Blydt-Hansen T. Optimizing the approach to monitoring allograft inflammation using serial urinary CXCL10/creatinine testing in pediatric kidney transplant recipients. Pediatric Transplantation. 2024;28(3). doi:10.1111/petr.14718

BibTeX
@article{BarrettChan2024,
  author = {Barrett-Chan, Ella and Wang, Li and Bone, Jeffrey and Thachil, Amy and Vytlingam, Kevin and Blydt-Hansen, Tom},
  title = {Optimizing the approach to monitoring allograft inflammation using serial urinary CXCL10/creatinine testing in pediatric kidney transplant recipients},
  journal = {Pediatric Transplantation},
  year = {2024},
  volume = {28},
  number = {3},
  doi = {10.1111/petr.14718}
}
Kostenlos starten →